Evidence map›Paper›PMID 37761882›Full record

ArticleGenes2023

An Automated Prognostic Model for Pancreatic Ductal Adenocarcinoma.

Ioannis Vezakis, Antonios Vezakis, Sofia Gourtsoyianni, Vassilis Koutoulidis, Andreas A Polydorou, George K Matsopoulos, Dimitrios D Koutsouris

Open access · goldAbstract read
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ioannis VezakisBiomedical Engineering Laboratory, School of Electrical & Computer Engineering, National Technical University of Athens, 9 Iroon Polytechniou St., 15780 Athens, Greece.ORCID 0000-0003-4976-4901
Antonios Vezakis2nd Department of Surgery, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 76 Vas. Sophias Ave., 11528 Athens, Greece.
Sofia Gourtsoyianni1st Department of Radiology, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 76 Vas. Sophias Ave., 11528 Athens, Greece.ORCID 0000-0001-6851-2502
Vassilis Koutoulidis1st Department of Radiology, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 76 Vas. Sophias Ave., 11528 Athens, Greece.ORCID 0000-0001-6281-8586
Andreas A Polydorou2nd Department of Surgery, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 76 Vas. Sophias Ave., 11528 Athens, Greece.ORCID 0000-0001-6165-3492
George K MatsopoulosBiomedical Engineering Laboratory, School of Electrical & Computer Engineering, National Technical University of Athens, 9 Iroon Polytechniou St., 15780 Athens, Greece.ORCID 0000-0002-2600-9914
Dimitrios D KoutsourisBiomedical Engineering Laboratory, School of Electrical & Computer Engineering, National Technical University of Athens, 9 Iroon Polytechniou St., 15780 Athens, Greece.ORCID 0000-0003-1205-9918
National and Kapodistrian University of Athens · GRNational Technical University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) constitutes a leading cause of cancer-related mortality despite advances in detection and treatment methods. While computed tomography (CT) serves as the current gold standard for initial evaluation of PDAC, its prognostic value remains limited, as it relies on diagnostic stage parameters encompassing tumor size, lymph node involvement, and metastasis. Radiomics have recently shown promise in predicting postoperative survival of PDAC patients; however, they rely on manual pancreas and tumor delineation by clinicians. In this study, we collected a dataset of pre-operative CT scans from a cohort of 40 PDAC patients to evaluate a fully automated pipeline for survival prediction. Employing nnU-Net trained on an external dataset, we generated automated pancreas and tumor segmentations. Subsequently, we extracted 854 radiomic features from each segmentation, which we narrowed down to 29 via feature selection. We then combined these features with the Tumor, Node, Metastasis (TNM) system staging parameters, as well as the patient's age. We trained a random survival forest model to perform an overall survival prediction over time, as well as a random forest classifier for the binary classification of two-year survival, using repeated cross-validation for evaluation. Our results exhibited promise, with a mean C-index of 0.731 for survival modeling and a mean accuracy of 0.76 in two-year survival prediction, providing evidence of the feasibility and potential efficacy of a fully automated pipeline for PDAC prognostication. By eliminating the labor-intensive manual segmentation process, our streamlined pipeline demonstrates an efficient and accurate prognostication process, laying the foundation for future research endeavors.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansPancreasPrognosisdeep learningmachine learningpancreatic cancerpancreatic ductal adenocarcinomapredictive modelingprognosticationradiomicssurvival

Identifiers

PMID37761882
PMCPMC10530933
OpenAlexW4386325655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.